| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1749-6632.2012.06674.X |
| P698 | PubMed publication ID | 22831177 |
| P2093 | author name string | Carsten Goessl | |
| William C Dougall | |||
| Paul J Kostenuik | |||
| Roger Dansey | |||
| Ada Braun | |||
| Rachel B Wagman | |||
| Leonid Katz | |||
| Holly Brenza Zoog | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats | Q28568938 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. | Q33733718 | ||
| Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys | Q33874897 | ||
| Mechanisms of bone metastasis | Q33977526 | ||
| Increased fracture rate in women with breast cancer: a review of the hidden risk | Q34004925 | ||
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 | ||
| Meta-analysis: excess mortality after hip fracture among older women and men. | Q34443074 | ||
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 | ||
| Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women | Q34656025 | ||
| Epidemiology and outcomes of osteoporotic fractures | Q34671295 | ||
| Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. | Q34680563 | ||
| Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 | ||
| Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
| Suppressive function of androgen receptor in bone resorption | Q35234694 | ||
| Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? | Q35643989 | ||
| Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. | Q35653722 | ||
| Prostate cancer clinical trial end points: "RECIST"ing a step backwards. | Q35751894 | ||
| Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
| Fracture risk in men with prostate cancer: a population-based study. | Q35876254 | ||
| Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. | Q36153174 | ||
| Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension | Q36153179 | ||
| Osteoporosis: a still increasing prevalence | Q36385297 | ||
| Review of adherence to medications for the treatment of osteoporosis | Q36417313 | ||
| Adherence to medications for the treatment of osteoporosis | Q36731600 | ||
| A systematic review of persistence and compliance with bisphosphonates for osteoporosis | Q36739641 | ||
| Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 | ||
| RANK ligand as a therapeutic target for bone metastases and multiple myeloma | Q36983217 | ||
| Osteotropic cancers: from primary tumor to bone | Q37218376 | ||
| Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. | Q37383740 | ||
| Impact of androgen deprivation therapy on cardiovascular disease and diabetes. | Q37583719 | ||
| Do RANKL inhibitors (denosumab) affect inflammation and immunity? | Q37767159 | ||
| Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis | Q37899689 | ||
| Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis | Q39730235 | ||
| Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis | Q39740475 | ||
| Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 | ||
| RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | Q40050213 | ||
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. | Q42648818 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. | Q43745339 | ||
| A method to assess the proportion of treatment effect explained by a surrogate endpoint | Q43825226 | ||
| Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs | Q43917199 | ||
| Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis | Q44486779 | ||
| Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group | Q44547450 | ||
| Regulatory effects of osteoprotegerin on cellular and humoral immune responses | Q44707640 | ||
| Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody | Q45419865 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. | Q45931469 | ||
| Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. | Q45962202 | ||
| Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. | Q45969997 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study | Q46307945 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Compliance with osteoporosis medications | Q46803624 | ||
| Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. | Q46809651 | ||
| Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses | Q46891798 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. | Q51565506 | ||
| Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. | Q51607043 | ||
| Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. | Q51703171 | ||
| Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases | Q57693579 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 29-40 | |
| P577 | publication date | 2012-07-25 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction | |
| P478 | volume | 1263 |
| Q35853244 | Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity |
| Q42586718 | CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany |
| Q56565085 | Denosumab for the treatment of osteoporosis. |
| Q89736900 | Immune system and bone microenvironment: rationale for targeted cancer therapies |
| Q39096364 | Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer |
| Q99614990 | NRF2 Is an Upstream Regulator of MYC-Mediated Osteoclastogenesis and Pathological Bone Erosion |
| Q36945036 | Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice |
| Q36898545 | RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease |
| Q33703763 | Recent advances in bone-targeted therapies of metastatic prostate cancer |
| Q37241261 | Role of osteoclasts in regulating hematopoietic stem and progenitor cells |
| Q54627328 | Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy. |
| Q35146317 | Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response |
| Q37274132 | Targeting the tumor microenvironment: from understanding pathways to effective clinical trials |
| Q92332147 | The evolving therapeutic landscape of genetic skeletal disorders |
| Q28078337 | What Is Breast in the Bone? |
| Q39223387 | miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease |
Search more.